TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15568582

Group type: EXPERIMENTAL
Intervention: Smoke Free Leitrim (SFL) programme
Number of subjects: 450

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: SFL group
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: SFL males
Number of subjects: 450

Group type: COMPARATOR
Intervention: Control males
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: SFL females
Number of subjects: 450

Group type: COMPARATOR
Intervention: Control females
Number of subjects: 450
Study: 11168602

Group type: EXPERIMENTAL
Intervention: Adjustable light-emitting diode device used to match flickering of auras.
Number of subjects: 11
Study: 9494831

Group type: EXPERIMENTAL
Intervention: La Crosse encephalitis consideration in diagnosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endemic areas
Number of subjects: 0
Study: 7847205

Group type: EXPERIMENTAL
Intervention: MR scans in participants with clinical histories of stroke (100 subjects)
Number of subjects: 303

Group type: COMPARATOR
Intervention: MR scans in participants without clinical histories of stroke (203 subjects)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: MR scans for large infarctlike lesions (> 3 mm)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: MR scans for small infarctlike lesions (≤ 3 mm)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: MR scans for sulcal and ventricular sizes and extent of white matter disease
Number of subjects: 303
Study: 2789586

Group type: EXPERIMENTAL
Intervention: Chromic catgut
Number of subjects: 100

Group type: COMPARATOR
Intervention: Silk
Number of subjects: 100
Study: 776152

Group type: EXPERIMENTAL
Intervention: Piracetam (pyrrolidine acetamide) at a dose of 80 mg/kg/day for 10 weeks.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group receiving customary treatment only.
Number of subjects: 20
Study: 7218393

Group type: EXPERIMENTAL
Intervention: Albumin resuscitation (average of 31 gms during operation, 207 gms during early postoperative period, 402 gm during mobilization period)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Non-albumin resuscitation (control group)
Number of subjects: 94
Study: 29968937

Group type: EXPERIMENTAL
Intervention: Fecal immunochemical test (FIT) with cut-off levels 20 μg Hb/g and 40 μg Hb/g for one sample
Number of subjects: 12383

Group type: EXPERIMENTAL
Intervention: Fecal immunochemical test (FIT) with mean of two samples at cut-off 40 μg Hb/g and 80 μg Hb/g
Number of subjects: 12383

Group type: EXPERIMENTAL
Intervention: Fecal immunochemical test (FIT) in men
Number of subjects: 12383

Group type: EXPERIMENTAL
Intervention: Fecal immunochemical test (FIT) in women with lowered cut-off from 40 to 20 μg Hb/g
Number of subjects: 12383

Group type: EXPERIMENTAL
Intervention: Fecal immunochemical test (FIT) levels for CRC and advanced adenomas (AA)
Number of subjects: 12383
Study: 29510001

Group type: EXPERIMENTAL
Intervention: Tildrakizumab IV doses of 0.1, 0.5, 3 and 10 mg/kg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Tildrakizumab SC doses of 50 or 200 mg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (IV and SC)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Tildrakizumab (IV and SC)
Number of subjects: 43
Study: 26975813

Group type: EXPERIMENTAL
Intervention: Intensive phototherapy
Number of subjects: 144

Group type: COMPARATOR
Intervention: Conventional phototherapy
Number of subjects: 144
Study: 23793255

Group type: EXPERIMENTAL
Intervention: Music lessons (12 sessions of 75 minutes each)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No music lessons (control group)
Number of subjects: 60
Study: 22176793

Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 21037189

Group type: EXPERIMENTAL
Intervention: Zirconia frameworks
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Metal frameworks
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Alumina frameworks
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: CZR Press veneer ceramics with zirconia frameworks
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Pulse interface veneer ceramics with metal frameworks
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Nonleucite-containing veneer ceramics with zirconia frameworks
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Leucite-containing pressed ceramics
Number of subjects: 259
Study: 17414240

Group type: EXPERIMENTAL
Intervention: 20-mg fluoxetine
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: 40-mg fluoxetine
Number of subjects: 411

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411
Study: 15840751

Group type: EXPERIMENTAL
Intervention: Monophasic oral contraceptive pill with lower dose of norethisterone
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Monophasic oral contraceptive pill with higher dose of norethisterone
Number of subjects: 23
Study: 12402610

Group type: EXPERIMENTAL
Intervention: Dressing film method (Group A) - exit site cleaned with povidone iodine solution once weekly, covered with gauze, sealed with dressing film
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Dressing film method (Group B) - exit site cleaned with povidone iodine solution once every 2 weeks, covered with gauze, sealed with dressing film
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Dressing film method (Group C) - exit site cleaned with povidone iodine solution once every 3 weeks, covered with gauze, sealed with dressing film
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Dressing film method (Group D) - exit site cleaned with povidone iodine solution once every 4 weeks, covered with gauze, sealed with dressing film
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Dressing film method (Group E) - exit site cleaned with povidone iodine solution once every 5 weeks, covered with gauze, sealed with dressing film
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Dressing film method (Group F) - exit site cleaned with povidone iodine solution once every 6 weeks, covered with gauze, sealed with dressing film
Number of subjects: 442

Group type: COMPARATOR
Intervention: Control group - exit site cleaned with povidone iodine solution daily, gauze dressing applied
Number of subjects: 442
Study: 10465325

Group type: EXPERIMENTAL
Intervention: Education on UTI
Number of subjects: 204

Group type: COMPARATOR
Intervention: Education on asthma
Number of subjects: 204
Study: 7881645

Group type: EXPERIMENTAL
Intervention: Continuous nebulization of terbutaline (16 mg over 8 hours)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intermittent nebulization of terbutaline (4 mg every 2 hours for 20 minutes)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Continuous nebulization of terbutaline
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intermittent nebulization of terbutaline
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups (Continuous and Intermittent nebulization)
Number of subjects: 16
Study: 2364920

Group type: EXPERIMENTAL
Intervention: Experimental diet (group A, 97 cases)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Normal diet (group B, 100 cases)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Experimental diet (group A)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Normal diet (group B)
Number of subjects: 197
Study: 417893

Group type: EXPERIMENTAL
Intervention: High pressure oxygen (HPO) with six fractions of 600 rad maximum tissue dose
Number of subjects: 505

Group type: COMPARATOR
Intervention: Air at atmospheric pressure with conventional small fraction daily radiotherapy
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Adjuvant high pressure oxygen (HPO) with large fraction radiotherapy
Number of subjects: 505
Study: 31846705

Group type: EXPERIMENTAL
Intervention: Bezlotoxumab
Number of subjects: 259

Group type: COMPARATOR
Intervention: No bezlotoxumab
Number of subjects: 259
Study: 31099188

Group type: EXPERIMENTAL
Intervention: Genetically-determined BMI
Number of subjects: 384838

Group type: EXPERIMENTAL
Intervention: Genetically-determined femoral neck BMD
Number of subjects: 384838

Group type: EXPERIMENTAL
Intervention: Low SBP
Number of subjects: 384838

Group type: COMPARATOR
Intervention: Other metabolic factors and CRP
Number of subjects: 384838
Study: 28364091

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment (targeting systolic BP <120 mm Hg)
Number of subjects: 9361

Group type: COMPARATOR
Intervention: Standard blood pressure treatment (targeting systolic BP <140 mm Hg)
Number of subjects: 9361
Study: 25901092

Group type: EXPERIMENTAL
Intervention: Low sodium condition (70±29 mmol/d)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Typical sodium condition (153±29 mmol/d)
Number of subjects: 17
Study: 23653366

Group type: EXPERIMENTAL
Intervention: Single-port access laparoscopic surgery
Number of subjects: 73

Group type: COMPARATOR
Intervention: Three-port laparoscopic surgery
Number of subjects: 73
Study: 21480207

Group type: EXPERIMENTAL
Intervention: INCB018424 (JAK1 and JAK2 inhibitor)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Myelofibrosis Symptom Assessment Form
Number of subjects: 87
Study: 19238255

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 microg Se/day for 3 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17545903

Group type: EXPERIMENTAL
Intervention: Spinal decompression (Group 1)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Decompression and instrumented posterolateral fusion (Group 2)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Decompression and instrumented posterolateral fusion plus transforaminal interbody fusion (TLIF) (Group 3)
Number of subjects: 44
Study: 14736627

Group type: EXPERIMENTAL
Intervention: 50% increase in the regular standing duration
Number of subjects: 26

Group type: COMPARATOR
Intervention: No increase in the regular standing duration (Control)
Number of subjects: 26
Study: 11734429

Group type: EXPERIMENTAL
Intervention: Budesonide (800 microg twice a day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 9413293

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (13 to 15 mg/kg daily)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 8035590

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine (60 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3552029

Group type: EXPERIMENTAL
Intervention: Lactitol
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sorbitol
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 31638477

Group type: EXPERIMENTAL
Intervention: Short-term aerobic exercise program (12 weeks)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no physical exercise)
Number of subjects: 63
Study: 31147684

Group type: EXPERIMENTAL
Intervention: Volumetric modulated arc therapy (VMAT) for GYN, rectal, H&N, and prostate cancer
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Volumetric modulated arc therapy (VMAT) for prostate cancer
Number of subjects: 344
Study: 28814394

Group type: EXPERIMENTAL
Intervention: Mediterranean/low-carbohydrate (MED/LC) diet plus 28 g walnuts/d
Number of subjects: 80

Group type: COMPARATOR
Intervention: Low-fat (LF) diet
Number of subjects: 80
Study: 26094328

Group type: EXPERIMENTAL
Intervention: Interferential current (IFC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 60
Study: 23395779

Group type: EXPERIMENTAL
Intervention: 250ml beetroot juice daily (active)
Number of subjects: 27

Group type: COMPARATOR
Intervention: 250ml nitrate-depleted beetroot juice (placebo)
Number of subjects: 27
Study: 21214895

Group type: EXPERIMENTAL
Intervention: Tele‐health supported Community COPD Service (two home visits with a specialist COPD clinician and daily tele‐monitoring over eight weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual Care (six home visits by specialist COPD clinicians over eight weeks)
Number of subjects: 60
Study: 19172536

Group type: EXPERIMENTAL
Intervention: 1 mg of 17beta-estradiol (E(2) group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (placebo group)
Number of subjects: 60
Study: 17175485

Group type: EXPERIMENTAL
Intervention: Fetoscopic laser therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amnioreduction
Number of subjects: 0
Study: 12653877

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 75 mg daily
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (target groups < or =90, < or =85, < or =80 mmHg)
Number of subjects: 18790

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Patients with diabetes
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Cost of avoiding a major CV event
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Base case analysis
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Sensitivity analysis
Number of subjects: 18790
Study: 10740633

Group type: EXPERIMENTAL
Intervention: High dose CDDP plus 5-FU regimen
Number of subjects: 321

Group type: COMPARATOR
Intervention: Standard therapy group (MMC and UFT)
Number of subjects: 321
Study: 8776549

Group type: EXPERIMENTAL
Intervention: Multiperspective Multidimensional Pain Assessment Protocol (MMPAP)
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: MMPAP
Number of subjects: 651
Study: 1732307

Group type: EXPERIMENTAL
Intervention: Waxed dental floss with greater tensile strength
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waxed dental floss with lower tensile strength
Number of subjects: 20
Study: 6685628

Group type: EXPERIMENTAL
Intervention: Single dose of [3H]‐dibromodulcitol (400 mg/m2)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Three smaller daily oral doses of [3H]‐dibromodulcitol (150‐180 mg/m2)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) concentration of [3H]‐dibromodulcitol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Plasma concentration of [3H]‐dibromodulcitol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Elimination half-life of [3H]‐dibromodulcitol from tissues
Number of subjects: 10
Study: 30934035

Group type: EXPERIMENTAL
Intervention: Expert surgeon group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Novice surgeon group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 29894926

Group type: EXPERIMENTAL
Intervention: Subcutaneous saline irrigation
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 185
Study: 25428583

Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin
Number of subjects: 1390

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1390

Group type: EXPERIMENTAL
Intervention: High serum endostatin
Number of subjects: 1390
Study: 23918843

Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise training (AET; n = 60)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Usual care (UC; n = 62)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Usual care participants who completed the 4-week posttrial exercise program
Number of subjects: 122
Study: 20681818

Group type: EXPERIMENTAL
Intervention: Microspheres
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Gel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 19786378

Group type: EXPERIMENTAL
Intervention: Nattokinase combined with red yeast rice (RYR) extract (300 mg of extract/capsule)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Nattokinase mono formula (50 mg/capsule)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 17079111

Group type: COMPARATOR
Intervention: MDRS total score
Number of subjects: 54

Group type: COMPARATOR
Intervention: MDRS Memory subscale
Number of subjects: 54

Group type: COMPARATOR
Intervention: MMSE
Number of subjects: 54

Group type: COMPARATOR
Intervention: MDRS total, Memory subscale, MMSE
Number of subjects: 54
Study: 15577134

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 7478
Study: 11375838

Group type: EXPERIMENTAL
Intervention: Patient-controlled IV meperidine (50 mg/h or more)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Patient-controlled IV meperidine (<50 mg/h)
Number of subjects: 259
Study: 8215265

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (75 mg/kg for children, 4 g for adults) for 5 days
Number of subjects: 59

Group type: COMPARATOR
Intervention: Chloramphenicol (60 mg/kg/day until defervescence, then 40 mg/kg/day) for 14 days
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 59

Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 59
Study: 3114803

Group type: EXPERIMENTAL
Intervention: Promethazine (12.5 mg, 25 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cinnarizine (30 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Scopolamine (0.6 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29168052

Group type: EXPERIMENTAL
Intervention: WL + AT
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: WL + RT
Number of subjects: 249

Group type: COMPARATOR
Intervention: WL
Number of subjects: 249
Study: 26282492

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation via intrathecal route
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation via intralesional route
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 21
Study: 25624389

Group type: EXPERIMENTAL
Intervention: Clonidine (5 μg/kg per day, divided into 8 doses, with possible dose escalation to maximum of 12 μg/kg per day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Morphine (0.4 mg/kg per day, with possible dose escalation to maximum of 1 mg/kg per day)
Number of subjects: 31
Study: 23438268

Group type: EXPERIMENTAL
Intervention: Viewing peers' Facebook photos (experimental group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Viewing sexually suggestive Facebook photos (Study 2 experimental group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Viewing nonsexually suggestive Facebook photos (Study 2 control group)
Number of subjects: 0
Study: 20873903

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Guided self-help based on cognitive behavioral therapy (CBTgsh)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Behavioral weight loss (BWL)
Number of subjects: 205
Study: 18258639

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (792 mg/d)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study: 16377385

Group type: EXPERIMENTAL
Intervention: Allopurinol, 100 to 300 mg/d
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual therapy (Control)
Number of subjects: 54
Study: 12796516

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vigabatrin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Remacemide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 0
Study: 10758361

Group type: EXPERIMENTAL
Intervention: Fluoroscopy (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Blind placement (Group B)
Number of subjects: 30
Study: 9264767

Group type: EXPERIMENTAL
Intervention: Leuprorelin 11.25 mg every three months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Leuprorelin 3.75 mg monthly
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 44
Study: 7886558

Group type: EXPERIMENTAL
Intervention: SK therapy
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: rt-PA therapy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 55
Study: 2429076

Group type: EXPERIMENTAL
Intervention: tibalosine 150 mg daily for 1 week
Number of subjects: 12

Group type: COMPARATOR
Intervention: naloxone (opioid receptor antagonist)
Number of subjects: 12
Study: 30134331

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17983 and lactulose
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo and lactulose
Number of subjects: 33
Study: 24418368

Group type: EXPERIMENTAL
Intervention: 50 IU kg(‐1) twice‐weekly prophylaxis regimen
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 100 IU kg(‐1) once‐weekly prophylaxis regimen
Number of subjects: 50

Group type: COMPARATOR
Intervention: On-demand therapy
Number of subjects: 50
Study: 21757275

Group type: EXPERIMENTAL
Intervention: Biodegradable fixation plates
Number of subjects: 200

Group type: COMPARATOR
Intervention: Titanium metal plates
Number of subjects: 200
Study: 20108160

Group type: EXPERIMENTAL
Intervention: Calcium and Magnesium (Ca/Mg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 19000393

Group type: EXPERIMENTAL
Intervention: MRI within 12 weeks of GP referral including a provisional orthopaedic appointment
Number of subjects: 553

Group type: COMPARATOR
Intervention: Orthopaedic appointment without prior MRI
Number of subjects: 553
Study: 15706463

Group type: EXPERIMENTAL
Intervention: SR142801
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 12845235

Group type: EXPERIMENTAL
Intervention: PMX-F treatment (group A, n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional treatment (group B, n = 10)
Number of subjects: 20
Study: 10827659

Group type: EXPERIMENTAL
Intervention: Topical regular insulin (Iletin‐II) applied four times a day until healed
Number of subjects: 11

Group type: COMPARATOR
Intervention: Normal saline applied four times a day until healed
Number of subjects: 11

Group type: COMPARATOR
Intervention: Solution containing the same amount of zinc
Number of subjects: 11
Study: 8690827

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100‐300 mg/day)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Clomipramine (100‐250 mg/day)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 79

Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 79